PURPOSE: The purpose of this study was to compare the effects of filgrastim, sargramostim, or sequential sargramostim and filgrastim on CD34 + cell yields and morbidity after myelosuppressive ...

A study published in the Journal of Managed Care & Specialty Pharmacy found that filgrastim and filgrastim-sndz were noninferior for the prevention of febrile neutropenia events that would require ...

The digital press release with multimedia content can be accessed here: Holzkirchen, September 3, 2015 - Sandoz, a Novartis company, announced today that Zarxio(TM) (filgrastim-sndz) is now available ...

Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the ...

A study presented at the annual meeting of the American Society of Hematology concluded that tbo-filgrastim is similar to filgrastim for ASCT mobilization in patients with MM or NHL. Tbo-filgrastim ...

Please provide your email address to receive an email when new articles are posted on . There was a substantial uptake in the use of alternative filgrastim products, including its biosimilar ...

Filgrastim alone and sequential sargramostim and filgrastim have been shown to be more effective than sargramostim alone in the mobilization of CD34 + cells after myelosuppressive chemotherapy (MC).

The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma. Stem cell transplantation is an important treatment method for ...

Review the side-effects of Filgrastim as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

New York, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Regional Outlook, ...

Below is a rundown of some recent developments in BPCIA litigations concerning biosimilars of Neupogen® (filgrastim) and/or Neulasta® (pegfilgrastim). Amgen v. Adello (filgrastim) As we previously ...

Please provide your email address to receive an email when new articles are posted on . The use of biosimilar biologics filgrastim-sndz and tbo-filgrastim increased substantially among Medicare ...